Effect of fluid resuscitation with balanced solutions on platelets: In vitro simulation of 20% volume substitution

Authors: Łukasz J. Krzych, Piotr F. Czempik

DOI: 10.5603/CJ.a2017.0054

Article type: Original articles

Submitted: 2017-02-08

Accepted: 2017-05-01

Published online: 2017-05-11

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
Effect of fluid resuscitation with balanced solutions on platelets: In vitro simulation of 20% volume substitution

Short title: Fluid resuscitation and platelets

Łukasz J. Krzych, Piotr F. Czempik

Department of Cardiac Anesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland

Address for correspondence: Piotr Filip Czempik, Department of Cardiac Anesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland, e-mail: piotr.czempik@wp.pl

Abstract
Background: Fluid resuscitation in massive bleeding may cause coagulation disorders by dilution of platelets and clotting factors or by the definite influence on their function. The aim of this study was to investigate the effects of balanced crystalloid and colloid solutions on platelets (PLT) in vitro using complex assessment of coagulation.

Methods: The study group was comprised of 32 American Society of Anesthesiologists physical status class I male volunteers, aged 21–35 (29 ± 4) years, weighting 59–103 (81.2 ± 9.8) kg. Whole blood samples were diluted at a 4:1 ratio with the following fluids: balanced crystalloid (Plasmalyte®), 6% hydroxyethyl starch 130/0.4 (Volulyte®) and succinylated gelatin (Geloplasma®). Coagulation was assessed using standard morphology, rotational thromboelastometry and aggregometry.

Results: Dilution with all fluids caused statistically significant drop in the number of platelets (p < 0.01) but the effect did not differ between solutions (p > 0.05 for all). Other platelet parameters, such as platelet distribution width, mean platelet volume and platelet-large cell ratio were not affected by the solutions. Haemodilution had no effect on platelet function (p = 0.1). Decreased platelet component of clot strength was found for all three fluids (p < 0.05), although the effect for colloids was more pronounced.

Conclusions: The effect of balanced crystalloids and colloids on platelet aggregation was insignificant, even after 20% volume substitution with the resuscitation fluids.

Key words: platelets, coagulopathy, rotational thromboelastometry, aggregometry, resuscitation fluids
Introduction

Prudent management of bleeding subjects or those non-bleeding but who are at high risk of hemorrhage is becoming more challenging.

Massive bleeding is considered generally as the loss of one blood volume within a 24 hour period or a 50% blood volume within 3 hours, or a rate of loss of 150 mL/min. It is a life-threatening condition encountered in many surgical fields [1] and in major trauma where it is the primary cause of death in up to one third of patients [2].

According to the current guidelines [3, 4], intravascular volume therapy is the first line treatment during massive bleeding. On the one hand, crystalloids and colloids are essential to restore cardiac output and improve tissue oxygenation in patients with hemorrhagic shock. Simultaneously, both expanders may cause or exaggerate bleeding diathesis. Depending on their constituents and/or carrier solution, they may impair blood coagulation in different ways. The effects may be mediated by dilution of platelets and clotting factors or by the specific influence on their function [5].

The aim herein was to investigate the effects of the frequently used balanced crystalloid and colloid solutions on platelets in vitro by means of a complex assessment of coagulation.

Methods

The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice (KNW/0022/KB1/158/15/16). Written informed consent was obtained from 32 American Society of Anesthesiologists (ASA) physical status class I male volunteers, aged 21–35 (29 ± 4) years, weighting 59–103 (81.2 ± 9.8) kg, with no history of coagulopathy. No drugs were allowed for one week and no alcohol or strenuous physical exercise for one day prior to blood sampling.

Sampling

Venous blood samples were drawn via a 16 or 18G indwelling cannula from an antecubital vein of a non-dominant arm. Only minimal stasis was allowed to reduce the risk of bias [6]. The first portion of blood (2 mL) was discarded and four blood samples were drawn: baseline (BL, 12.5 mL) and one blood sample (10 mL) for every study fluid. Samples were collected in citrated blood tubes (S-Monovette, Sarstedt, Germany) for complete blood count (CBC) and rotational thromboelastometry analysis, and hirudin blood tubes (S-Monovette,
Sarstedt, Germany) for platelet aggregometry. Hirudin test tubes were used because alternative anticoagulants have been shown to bias the results of multiple electrode aggregometry (MEA) [7]. Immediately following the collection of samples they were processed using rotational thromboelastometry or sent to the central hospital laboratory for analysis. Samples were delivered to the laboratory in person because pneumatic tube transport systems have been shown to affect determinations made with MEA [8, 9].

**Haemodilution**

The study solutions included balanced crystalloid (Plasmalyte®, Baxter) (PL), 6% hydroxyethyl starch 130/0.4 (Volulyte®, Fresenius Kabi) (VL) and succinylated gelatin (Geloplasma®, Fresenius Kabi) (GEL). Whole blood samples were diluted at a 4:1 ratio with the study fluids to make an end-concentration of 20 vol.% for each solution, equivalent to an infusion of about 1 L into a 70 kg person. Taking into account mean weight of volunteers (81.2 ± 9.8 kg), the average amount of study solution administered in this recreated scenario was 15 mL/kg. The investigator performing dilutions was not blinded to test solutions used.

**Thromboelastometry**

Rotational thromboelastometry analysis was carried out using a four-channel ROTEM® delta analyzer (Tem Innovations GmbH, Germany), ROTEM-based assays were allowed to run for 30 min. Blood samples were analyzed immediately after sampling to minimize a pre-analytical error. The ROTEM assays performed were whole blood INTEM, EXTEM and FIBTEM. The INTEM (describing intrinsic coagulation pathway) was not related with study procedures. The EXTEM is an extrinsic coagulation assay initiated by the addition of a tissue factor. The FIBTEM assay measures effect of fibrin on clot firmness and uses cytochalasin D to inhibit platelets. In both former assays were measured at maximum clot firmness (MCF), i.e. parameter influenced by platelets, fibrin and factor XIII. The MCF value was used to calculate maximum clot elasticity (MCE) for both assays using the formula MCE = 100xMCF/100-MCF. Assessment of platelet contribution to clot strength was measured according to formula ΔMCE = MCE\textsubscript{EXTEM}−MCE\textsubscript{FIBTEM}.

**Aggregometry**

MEA was applied using Multiplate analyzer (Roche Diagnostics GmbH, Germany) along with the thrombin receptor activating peptide-6 (TRAP-6) as a platelet activator.
Aggregation units (AU) were calculated. The reference values provided by the laboratory were 941–1563 AU*min.

**Standard tests**

Standard laboratory test (SLT) included CBC with assessment of platelets (PLT) (reference value 150000–450000/µL) and allied parameters, e.g. platelet distribution width (PDW), mean platelet volume (MPV) and platelet-large cell ratio (P-LCR).

**Statistical analysis**

The statistical analysis was performed using the licensed MedCalc software (version 16.1 2016, MedCalc Software bvba, Belgium). The quantitative variables are presented as a median (interquartile range, IQR) or a mean ± standard deviation (SD). The type of distribution was verified using Shapiro-Wilk test. The differences between results obtained for particular study solutions were analyzed using repeated measures of ANOVA or Friedman test. Post-hoc comparisons were performed using the Scheffe test or the Conover post-hoc analysis, when appropriate. The level of statistical significance was set at p < 0.05.

**Results**

Dilution with all fluids caused a statistically significant drop in the number of platelets (p < 0.01) but the effect did not differ between solutions (p > 0.05 for all) (Fig. 1).

The effect of study solution on degree of haemodilution is depicted in Fig. 2.

The blood platelet counts following administration of PL, VL and GEL dropped by 21.6%, 19.8% and 25.5%, respectively. Other platelet parameters, such PDW, MPV and P-LCR were not affected by the solutions (Fig. 3A–C).

Haemodilution had no effect on platelet function as evidenced by MEA (p = 0.1) (Fig. 4). The platelet contribution to clot strength as determined by ΔMCE is shown in Figure 5. Decreased platelet component of clot strength was found for all three fluids (p < 0.05), although the effect for colloids was more pronounced. Platelet component of clot strength decreased to 83.2%, 78.1%, 77.4% for PL, VL and GEL, respectively.

**Discussion**

Dilution due to aggressive fluid resuscitation leads to decreased concentration of clotting factors and number of platelets. It does, however, remain interesting as to whether this effect is caused by either the reduction in quantity or quality in blood coagulation, or
both. The present study evaluated the effect of three commonly used intravenous fluids on platelets in an in vitro setting. Although the 20 vol.% dilution with study fluids caused significant drop in platelet count, there was no effect on platelet aggregation, and all values for functional and standard tests remained within reference laboratory ranges.

These results are in line with previous investigations showing that crystalloids have less effect on blood coagulation compared to colloids [10]. Contrary to a few other studies we revealed that platelet function was not affected by the tested solutions.

Williams et al. [5] found that platelet function was impaired only at high levels of haemodilution (40% dilution with 6% HES 130/0.4 and 0.9% NaCl) as evidenced by light transmission aggregometry (LTA) or MEA. Minor or moderate haemodilution have shown no effect on platelet function. Both of those examined in this study, fluids affected platelet function to a similar insignificant degree. This discrepancy may be explained by the fact that MEA results were interfered with when the platelet count was lower than 150 000/µL [11], although large variations have been observed between individuals and normal values of MEA were being reported for platelet counts as low as 50 000/µL [12].

Treib et al. [13] noticed decreased MPV following HES administration but this effect was seen after several days of its administration. This study did not observe a similar effect, probably due to short exposure to HES.

Liu et al. [14] showed that HES 200/0.5 and 130/0.4 inhibited platelet aggregation ex vivo and the effect was more noticeable with dilutions higher than 20%, and for HES with higher molecular weight. Shaden et al. [15] showed that only saline-based HES 130/0.42 solutions as opposed to balanced solution-based HES administered at a dose of 20ml kg⁻¹ significantly decreased platelet aggregation in response to ADP in healthy volunteers.

In a recent study Li et al. [16] showed no changes in Multiplate (ADP-test, TRAP-test) of up to 1000 mL of HES 130/0.42 in neurosurgical patients.

Evans et al. [17] investigated the impact of two different gelatin-based fluids on platelet function in vitro. The authors added fluids to make an end-concentration of 40%. Both solutions prevented platelet aggregation induced by ristocetin, although platelet inhibition was more pronounced after Haemaccel®, probably due to high Ca²⁺ content. Haemaccel® also inhibited aggregation induced by other activating factors, namely adenosine diphosphate (ADP), platelet activating factor (PAF), collagen, thromboxan A2 (TXA2) and epinephrine. Ristocetin induces platelet aggregation by mechanism involving the von Willebrand factor and its glycoprotein Ib receptor present on a platelet surface. In this study TRAP-6 was used for platelet activation. It is known that increasing concentration of Ca²⁺
impairs platelet aggregation in vitro [18]. In the present study balanced crystalloids were used and colloids with no calcium added so this effect was not an issue.

In a prospective study in which Gelofusine® (4% succinylated gelatin) was infused into young volunteers, the authors reported a significant increase in bleeding time, impairment of ristocetin-induced platelet aggregation, which might have been related to gelatin-induced deficiency of the von Willebrand factor [19]. Some authors emphasize a beneficial effect of gelatins as their antiaggregatory properties might provide a degree of protection from thrombosis in trauma patients [20]. Platelets have been observed to be main contributors to increased coagulation after trauma [21]. Similarly HES-induced coagulopathy might counteract the effects of intra-operative activation of coagulation [22].

It is important to bear in mind a differentiation between platelet aggregation and adhesion as far as primary haemostasis is concerned. None of the in vitro tests of coagulation was able to measure impact of vascular endothelium on haemostasis. ROTEM as a diagnostic measure using a whole blood sample and taking into account other physiologic parameters (e.g. temperature, ionized calcium, presence of anticoagulants) is the most accurate test for diagnosing actual coagulopathy but ROTEM has too low shear stress and the impact of a normal endothelial effect or defect as during trauma is missing either in ROTEM or MEA.

An important topic is the impact on bleeding of synthetic colloids used for priming of cardiopulmonary bypass circuit in cardiac surgery. Cardiac surgery is a discipline where bleeding is common. Based on the results of the present in vitro research, the use of succinylated gelatin and HES as a priming solution should be cautious [23].

**Limitations of the study**

First of all, only 20 vol. % blood dilution was made, which may be insufficient to observe coagulation abnormalities. Clinically relevant effects of synthetic plasma expanders on bleeding are present when large volumes (> 20 mL/kg) are infused or when patients present a priori with coagulopathy [20]. This study attempted to mitigate this drawback using the most sensitive functional testing, i.e. ΔMCE in ROTEM and MEA analysis. The study herein ran two assays simultaneously, one with platelet inhibitors and one without, to identify specific coagulopathy caused by platelets. The effect of the study solutions on platelet component of clot strength as measured by ROTEM parameters showed decreased MCE for all three study solutions, which was more pronounced for HES and gelatin. Measuring platelet-dependent clot strength by elasticity as opposed to clot amplitude is sound because the relationship between clot amplitude and clot elasticity is nonlinear and clot elasticity,
unlike clot amplitude, reflects the force of the blood clot resisting rotation within the device [24]. Moreover, clot strength as measured by clot amplitude, depends not only on platelets, but also on fibrinogen and factor XIII concentrations, although the relative contribution of platelets is approximately 80% [21]. In clot elasticity platelet contribution is 87–94% [25]. Secondly, the quantity of von Willebrand factor may impact clot stability and resulting bleeding time [19] and postoperative blood loss [26], however in the present study its concentration was not measured. Thirdly, MEA was used for testing platelet function, whereas the most objective test of platelet function is LTA. Another limitation is the fact that observations are based on in vitro experiments which may differ from those caused by true fluid resuscitation, including recruitment of additional resources of the coagulation system, response to tissue and endothelial injuries, as well as changes in kinetics, volume of distribution or acid-base balance. Therefore, on one hand, in vivo studies deliver more physiological data. On the other hand, findings in healthy volunteers would differ also from those in actual massive bleeding. Finally, there was no control group for balanced solutions. It was however, revealed that carrier solution had little impact on platelet aggregation and clot formation [15, 27].

Conclusions

The effect of balanced crystalloids and colloids on platelet aggregation is insignificant, even after 20% volume substitution with the resuscitation fluids.

Acknowledgements

We express our gratitude to the personnel of the central hospital laboratory in the Silesian Centre for Heart Diseases in Zabrze for their voluntary extra work providing determinations for this study.

Conflict of interest: None declared

References


10. Skhirtladze K, Base EM, Lassnigg A, et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation


27. Casutt M, Kristoffy A, Schuepfer G, et al. Effects on coagulation of balanced (130/0.42) and non-balanced (130/0.4) hydroxyethyl starch or gelatin compared with

**Figure 1.** Effect of study solutions on platelet count.

**Figure 2.** Effect of study solution on hematocrit.

**Figure 3A.** Effect of study solutions on platelet distribution width (PDW);

**Figure 3B.** Effect of study solutions on mean platelet volume (MPV).

**Figure 3C.** Effect of study solutions on platelet-large cell ratio (P-LCR).

**Figure 4.** Effect of study solutions on platelet aggregation assessed by thrombin receptor activating peptide (TRAP).

**Figure 5.** Effect of study solutions on platelet-dependent clot strength.
p<0.05: BL vs. PL; BL vs. VL; BL vs. GEL
p<0.05: BL vs. PL, VL, GEL; PL vs. BL, VL; VL vs. BL, PL; GEL vs. BL
The box plot shows the distribution of MPV [10^{-15}L] for different groups labeled BL, PL, VL, and GEL. The p-value for the comparison is p=0.41.
p<0.05: BL vs. PL, VL, GEL; PL vs. BL, VL, GEL; VL vs. BL, PL; GEL vs. BL, PL